Phenotypes associated with this allele

• Allele Symbol: Ccn2⁺
• Allele Name: wild type
• Allele ID: MGI:2430667
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Ccn2^tm1.1(folA/cre)Hze/Ccn2^+	involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * C57BL/6NCr	MGI:5707415
ht2	Ccn2^tm1Mga/Ccn2^+	involves: 129S6/SvEvTac * C57BL/6NTac	MGI:4822059
cn3	Ccn2^tm2Mae/Ccn2^+ Tg(EIIa-cre)C5379Lmgd/?	involves: 129S6/SvEvTac	MGI:4838160
cn4	Ccn2^tm2Mae/Ccn2^+ Tg(CAG-cre/Esr1*)5Amc/?	involves: 129S6/SvEvTac * C57BL/6 * CBA	MGI:4838161
cn5	Ccn2^tm2Mae/Ccn2^+ Tg(EIIa-cre)C5379Lmgd/?	involves: 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:4838158

Genotype
MGI:5707415

ht1

• Allelic Composition: Ccn2^{tm1.1(folA/cre)Hze}/Ccn2⁺
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * C57BL/6NCr

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:227758 )

• Heterozygous mice are viable and fertile with no gross physical or behavioral abnormalities.

Genotype
MGI:4822059

ht2

• Allelic Composition: Ccn2^tm1Mga/Ccn2⁺
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6NTac

skeleton

decreased bone mineral density ( J:163027 )

• at 1 month of age the bone volume to tissue volume ratio is reduced by 30-45%

• however, by 4 and 6 months of age no difference in the bone volume to tissue volume ratio is detected

abnormal trabecular bone morphology ( J:163027 )

• at 1 month of age the number of trabeculae is reduced but trabecular thickness is not significantly reduced

Genotype
MGI:4838160

cn3

• Allelic Composition: Ccn2^tm2Mae/Ccn2⁺; Tg(EIIa-cre)C5379Lmgd/?
• Genetic Background: involves: 129S6/SvEvTac

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:165111 )

• Background Sensitivity: no heterozygous embryos after E12.5

embryo

abnormal pharyngeal arch development ( J:165111 )

• pharyngeal arches remain open

embryonic growth retardation ( J:165111 )

• small and embryonic development is delayed at E10.5

cardiovascular system

abnormal vasculogenesis ( J:165111 )

• less visible vasculature

craniofacial

abnormal facial morphology ( J:165111 )

• shortened face in mice surviving to adulthood (4/81)

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)

limbs/digits/tail

short tail ( J:165111 )

• in mice surviving to adulthood (4/81)

kinked tail ( J:165111 )

• in mice surviving to adulthood (4/81)

skeleton

abnormal bone structure ( J:165111 )

• smaller bone area in mice surviving to adulthood (4/81)

decreased bone mineral content ( J:165111 )

• in mice surviving to adulthood (4/81)

growth/size/body

abnormal facial morphology ( J:165111 )

• shortened face in mice surviving to adulthood (4/81)

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)

embryonic growth retardation ( J:165111 )

• small and embryonic development is delayed at E10.5

decreased lean body mass ( J:165111 )

• in mice surviving to adulthood (4/81)

hearing/vestibular/ear

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)

Genotype
MGI:4838161

cn4

• Allelic Composition: Ccn2^tm2Mae/Ccn2⁺; Tg(CAG-cre/Esr1*)5Amc/?
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * CBA

normal phenotype

no abnormal phenotype detected ( J:165111 )

• tamoxifen induced cre expression has no effect on phenotype up to 3 months after treatment

Genotype
MGI:4838158

cn5

• Allelic Composition: Ccn2^tm2Mae/Ccn2⁺; Tg(EIIa-cre)C5379Lmgd/?
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * FVB/N

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:165111 )

• Background Sensitivity: no heterozygous embryos after E14.5

embryo

embryonic growth retardation ( J:165111 )

• small and embryonic development is delayed

decreased embryo size ( J:165111 )

cardiovascular system

abnormal vasculogenesis ( J:165111 )

• poor vascularization at E13.5-14.5

vision/eye

abnormal eye development ( J:165111 )

• eye is less developed at E13.5-14.5

craniofacial

short face ( J:165111 )

• shortened face in mice surviving to adulthood (4/81)

facial cleft ( J:165111 )

lateral facial cleft ( J:165111 )

• at E13.5-14.5

midline facial cleft ( J:165111 )

• at E13.5-14.5

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)

limbs/digits/tail

short tail ( J:165111 )

• in mice surviving to adulthood (4/81)

kinked tail ( J:165111 )

• in mice surviving to adulthood (4/81)

skeleton

abnormal bone structure ( J:165111 )

• smaller bone area in mice surviving to adulthood (4/81)

decreased bone mineral content ( J:165111 )

• in mice surviving to adulthood (4/81)

growth/size/body

short face ( J:165111 )

• shortened face in mice surviving to adulthood (4/81)

facial cleft ( J:165111 )

lateral facial cleft ( J:165111 )

• at E13.5-14.5

midline facial cleft ( J:165111 )

• at E13.5-14.5

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)

embryonic growth retardation ( J:165111 )

• small and embryonic development is delayed

decreased embryo size ( J:165111 )

decreased lean body mass ( J:165111 )

• in mice surviving to adulthood (4/81)

hearing/vestibular/ear

small ears ( J:165111 )

• in mice surviving to adulthood (4/81)